M&G Plc Decreases Stake in Illumina, Inc. (NASDAQ:ILMN)

M&G Plc cut its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.1% in the third quarter, Holdings Channel.com reports. The institutional investor owned 146,383 shares of the life sciences company’s stock after selling 1,571 shares during the period. M&G Plc’s holdings in Illumina were worth $19,030,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Primecap Management Co. CA grew its holdings in shares of Illumina by 462.5% in the second quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock valued at $253,514,000 after purchasing an additional 1,997,010 shares in the last quarter. Millennium Management LLC grew its stake in shares of Illumina by 305.0% in the 2nd quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock worth $155,067,000 after buying an additional 1,118,747 shares in the last quarter. Capital World Investors grew its stake in shares of Illumina by 41.1% in the 1st quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company’s stock worth $378,111,000 after buying an additional 801,814 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Illumina in the 2nd quarter worth about $77,628,000. Finally, Swedbank AB bought a new position in shares of Illumina in the 1st quarter valued at about $99,682,000. Institutional investors own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

ILMN has been the topic of several analyst reports. TD Cowen boosted their price objective on Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research note on Tuesday. JPMorgan Chase & Co. increased their price target on Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a report on Tuesday. Citigroup lifted their price objective on shares of Illumina from $155.00 to $190.00 and gave the stock a “buy” rating in a research note on Tuesday. UBS Group raised their target price on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a report on Tuesday. Finally, Daiwa America upgraded shares of Illumina to a “strong-buy” rating in a report on Friday, August 16th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Illumina presently has a consensus rating of “Moderate Buy” and an average target price of $162.18.

Illumina Stock Up 2.2 %

NASDAQ:ILMN opened at $155.15 on Friday. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.11 and a quick ratio of 0.86. Illumina, Inc. has a 1-year low of $89.00 and a 1-year high of $156.66. The company has a 50-day moving average of $137.27 and a 200 day moving average of $123.12. The firm has a market cap of $24.72 billion, a PE ratio of -15.58 and a beta of 1.13.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 6.36%. The company’s quarterly revenue was down 3.5% on a year-over-year basis. During the same period last year, the firm earned $0.33 earnings per share. As a group, research analysts anticipate that Illumina, Inc. will post 3.62 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.